Heterogeneity of leukemia stem cell candidates at diagnosis of acute myeloid leukemia and their clinical significance

Experimental Hematology

Volumn 40, Issue 2, 2012, Pages 155-165.e1

  Ran, Dan ^a   Schubert, Mario ^a   Taubert, Isabel ^a   Eckstein, Volker ^a   Bellos, Frauke ^a   Jauch, Anna ^a   Chen, Hui ^b   Bruckner, Thomas ^a   Saffrich, Rainer ^a   Wuchter, Patrick ^a   Ho, Anthony D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER STEM CELL; CELL HETEROGENEITY; CELL INTERACTION; CELL SUBPOPULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; STEM CELL EXPANSION; STEM CELL NICHE;

EID: 84855610965     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.10.005     Document Type: Article

References (36)

1. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
2. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
3. Sutherland H.J., Blair A., Zapf R.W. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 1996, 87:4754-4761.
4. Jordan C.T., Upchurch D., Szilvassy S.J., et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14:1777-1784.
5. Huntly B.J., Gilliland D.G. Cancer biology: summing up cancer stem cells. Nature 2005, 435:1169-1170.
6. van Rhenen A., Feller N., Kelder A., et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005, 11:6520-6527.
7. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
8. Pearce D.J., Taussig D., Zibara K., et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006, 107:1166-1173.
9. Taussig D.C., Vargaftig J., Miraki-Moud F., et al. Leukemia initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction. Blood 2010, 115:1976-1984.
10. Terwijn M., Feller N., van Rhenen A., et al. Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. Eur J Cancer 2009, 45:1692-1699.
11. Terwijn M, Rutten AP, Kelder A, etal. Accurate detection of residual leukemic stem cells In remission bone marrow predicts relapse in acute myeloid leukemia patients. Blood (ASH Annual Meeting Abstracts). 2010;116:Abstract 759.
12. Rosen J.M., Jordan C.T. The increasing complexity of the cancer stem cell paradigm. Science 2009, 324:1670-1673.
13. Capoccia B.J., Robson D.L., Levac K.D., et al. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood 2009, 113:5340-5351.
14. Hess D.A., Wirthlin L., Craft T.P., et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006, 107:2162-2169.
15. Storms R.W., Trujillo A.P., Springer J.B., et al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci U S A 1999, 96:9118-9123.
16. Gentry T., Foster S., Winstead L., Deibert E., Fiordalisi M., Balber A. Simultaneous isolation of human BM hematopoietic, endothelial and mesenchymal progenitor cells by flow sorting based on aldehyde dehydrogenase activity: implications for cell therapy. Cytotherapy 2007, 9:259-274.
17. Hess D.A., Meyerrose T.E., Wirthlin L., et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004, 104:1648-1655.
18. Ran D., Schubert M., Pietsch L., et al. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol 2009, 37:1423-1434.
19. Schubert M., Herbert N., Taubert I., et al. Differential survival of AML subpopulations in NOD/SCID mice. Exp Hematol 2011, 39:250-263.
20. Punzel M., Zhang T., Liu D., Eckstein V., Ho A.D. Functional analysis of initial cell divisions defines the subsequent fate of individual human CD34(+)CD38(-) cells. Exp Hematol 2002, 30:464-472.
21. Punzel M., Lui D., Zhang T., Eckstein V., Miesala K., Ho A.D. The symmetry of initial divisions of human hematopoietic progenitors is altered only by the cellular microenvironment. Exp Hematol 2003, 31:339-347.
22. Levis M., Murphy K.M., Pham R., et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 2005, 106:673-680.
23. Oostendorp R.A., Audet J., Miller C., Eaves C.J. Cell division tracking and expansion of hematopoietic long-term repopulating cells. Leukemia 1999, 13:499-501.
24. Vitacolonna M., Schubert M., Herbert N., et al. Improved T and B cell recovery by the transfer of slowly dividing human hematopoietic stem cells. Leuk Res 2010, 34:622-630.
25. Young J.C., Varma A., DiGiusto D., Backer M.P. Retention of quiescent hematopoietic cells with high proliferative potential during exvivo stem cell culture. Blood 1996, 87:545-556.
26. Pearce D.J., Taussig D., Simpson C., et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005, 23:752-760.
27. Croker A.K., Goodale D., Chu J., et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2009, 13:2236-2252.
28. Ma S., Chan K.W., Lee T.K., et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008, 6:1146-1153.
29. Ucar D., Cogle C.R., Zucali J.R., et al. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 2009, 178:48-55.
30. Ginestier C., Hur M.H., Charafe-Jauffret E., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
31. Chu P., Clanton D.J., Snipas T.S., et al. Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 2009, 124:1312-1321.
32. Cheung A.M., Wan T.S., Leung J.C., et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007, 21:1423-1430.
33. Notta F., Mullighan C.G., Wang J.C., et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469:362-367.
34. Anderson K., Lutz C., van Delft F.W., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
35. Goarden N., Marchi E., Atzberger A., et al. Coexistence of LMPP-like and GMP-like leukemia stem cells inacute myeloid leukemia. Cancer Cell 2011, 19:138-152.
36. Brandwein J.M., Gupta V., Schuh A.C., et al. Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy. Am J Hematol 2008, 83:54-58.